Soraya Benchikh El Fegoun
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Soraya Benchikh El Fegoun has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Andreas Tiede
Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany
2 shared publications Joanna A. Davis
Miami, FL, USA
2 shared publicationsRichard Habis
Psyma Group AG, Rückersdorf, Germany
2 shared publications- Robert Klamroth
Department of Internal Medicine, Vivantes Clinic Friedrichshain, Berlin, Germany
2 shared publications - Víctor Jiménez-Yuste
Hematology and Hemotherapy Unit, La Paz University Hospital-IdiPAZ, Madrid, Spain
2 shared publications A. Rojas‐Rios
Novo Nordisk A/S, Søborg, Denmark
1 shared publication
Latest Publications
- Open Access
- 25 September 2021
- Published by Wiley in Haemophilia
- Vol. 28 (1) , 27-35
Post‐hoc analysis on the long‐term response to fixed‐dose prophylaxis with N8‐GP in patients with haemophilia A
Introduction Challenges with personalised prophylaxis in haemophilia remain, including designing unique dosing schedules that require continual adjustments and monitoring using complex sampling procedures. Aim To assess long-term efficacy and pharmacokinetic outcomes with fixed-dose N8-GP prophylaxis. Methods Descriptive analyses were performed on data from the pathfinder 2 and pathfinder 5 trials of patients with severe haemophilia A. Bleed frequency and reoccurrence were assessed in relation to several clinical criteria of interest. Bleed risk relative to time since last dose was assessed using calculated annualised bleeding rate (ABR). Long-term ABR and mean factor VIII (FVIII) trough levels were assessed in patients who received consistent N8-GP prophylaxis every 4 days (Q4D). Results During pathfinder 2, 117/136 patients with study-drug exposure of ≥600 days experienced bleeding episodes; 8.6% of bleeds were reoccurring bleeds; bleed reoccurrence decreased over time. For patients who received consistent Q4D prophylaxis across the trial (n = 61), mean ABR decreased from 3.5 bleeds/year (Year 1) to 1.6 bleeds/year (Year 6); mean FVIII trough levels stabilised at approximately 5% (Year 6). Across patients who received prophylaxis at some point during pathfinder 2 (n = 177), 125/126 (99%) reoccurring bleeds were joint bleeds. For patients receiving Q4D prophylaxis, bleeding risk generally increased as the time since the last prophylaxis dose increased. A similar reduction in ABR and stabilisation of trough level was observed in pathfinder 5. Conclusion Long-term exposure (> 5 years) to fixed-dose N8-GP prophylaxis resulted in a protective haemostatic effect, with reduction in bleed frequency and reoccurrence, and stabilisation of FVIII trough level over time.
- 25 September 2021
- Published by Wiley in Haemophilia
- Vol. 28 (1) , 27-35
Open AccessPost‐hoc analysis on the long‐term response to fixed‐dose prophylaxis with N8‐GP in patients with haemophilia A
Introduction Challenges with personalised prophylaxis in haemophilia remain, including designing unique dosing schedules that require continual adjustments and monitoring using complex sampling procedures. Aim To assess long-term efficacy and pharmacokinetic outcomes with fixed-dose N8-GP prophylaxis. Methods Descriptive analyses were performed on data from the pathfinder 2 and pathfinder 5 trials of patients with severe haemophilia A. Bleed frequency and reoccurrence were assessed in relation to several clinical criteria of interest. Bleed risk relative to time since last dose was assessed using calculated annualised bleeding rate (ABR). Long-term ABR and mean factor VIII (FVIII) trough levels were assessed in patients who received consistent N8-GP prophylaxis every 4 days (Q4D). Results During pathfinder 2, 117/136 patients with study-drug exposure of ≥600 days experienced bleeding episodes; 8.6% of bleeds were reoccurring bleeds; bleed reoccurrence decreased over time. For patients who received consistent Q4D prophylaxis across the trial (n = 61), mean ABR decreased from 3.5 bleeds/year (Year 1) to 1.6 bleeds/year (Year 6); mean FVIII trough levels stabilised at approximately 5% (Year 6). Across patients who received prophylaxis at some point during pathfinder 2 (n = 177), 125/126 (99%) reoccurring bleeds were joint bleeds. For patients receiving Q4D prophylaxis, bleeding risk generally increased as the time since the last prophylaxis dose increased. A similar reduction in ABR and stabilisation of trough level was observed in pathfinder 5. Conclusion Long-term exposure (> 5 years) to fixed-dose N8-GP prophylaxis resulted in a protective haemostatic effect, with reduction in bleed frequency and reoccurrence, and stabilisation of FVIII trough level over time.
- 8 April 2020
- Published by Wiley in Haemophilia
- Vol. 26 (4) , E205-E208
A survey among patients with haemophilia and inhibitors or their caregivers, seeking treatment in non‐haemophilia treatment centres
- 8 April 2020
- Published by Wiley in Haemophilia
- Vol. 26 (4) , E205-E208
A survey among patients with haemophilia and inhibitors or their caregivers, seeking treatment in non‐haemophilia treatment centres
- 9 March 2020
- Published by Wiley in Haemophilia
- Vol. 26 (3) , 422-430
Barriers and challenges for the fast treatment of bleeds in the non‐haemophilia treatment centre hospital setting
Introduction Early treatment for acute bleeds in patients with haemophilia and inhibitors is feasible when patients are managed in haemophilia treatment centres (HTCs). Patients may need to attend non‐HTCs for out‐of‐hours emergency care, especially if HTCs are not local and/or transport is difficult. Aim We evaluated the barriers to the fast treatment of bleeds in patients with haemophilia and inhibitors presenting at non‐HTCs. Methods Healthcare professionals (HCPs) from non‐HTCs in the United States (n = 218) and Germany (n = 98) were selected from validated online panels and invited to participate in a survey (October‐November 2017). Results A mean of 6 (US) and 5 (German) patients with haemophilia and inhibitors were managed for bleeds by these HCPs over 12 months; patient characteristics were similar in both countries. The main HCPs involved in treating bleeds were emergency room specialists (94%) and haematologists (91%) (US); haematologists (79%) and anaesthesiologists (59%) (Germany). Only 26% (US) and 28% (Germany) of HCPs had access to treatment guidelines for these patients; access to bypassing agents was similarly limited: 44% (US) and 38% (Germany) of HCPs reported their institution did not stock these agents. In both countries, key reasons for delaying treatment were lack of bypassing agent availability, HCP experience/education of bleed disorders and internal process time. Conclusion Barriers to fast treatment of bleeds in patients with haemophilia and inhibitors were identified in non‐HTCs in the United States and Germany. These could be reduced by improving the availability of treatment guidelines, bypassing agents and HCP education/training.
- 9 March 2020
- Published by Wiley in Haemophilia
- Vol. 26 (3) , 422-430
Barriers and challenges for the fast treatment of bleeds in the non‐haemophilia treatment centre hospital setting
Introduction Early treatment for acute bleeds in patients with haemophilia and inhibitors is feasible when patients are managed in haemophilia treatment centres (HTCs). Patients may need to attend non‐HTCs for out‐of‐hours emergency care, especially if HTCs are not local and/or transport is difficult. Aim We evaluated the barriers to the fast treatment of bleeds in patients with haemophilia and inhibitors presenting at non‐HTCs. Methods Healthcare professionals (HCPs) from non‐HTCs in the United States (n = 218) and Germany (n = 98) were selected from validated online panels and invited to participate in a survey (October‐November 2017). Results A mean of 6 (US) and 5 (German) patients with haemophilia and inhibitors were managed for bleeds by these HCPs over 12 months; patient characteristics were similar in both countries. The main HCPs involved in treating bleeds were emergency room specialists (94%) and haematologists (91%) (US); haematologists (79%) and anaesthesiologists (59%) (Germany). Only 26% (US) and 28% (Germany) of HCPs had access to treatment guidelines for these patients; access to bypassing agents was similarly limited: 44% (US) and 38% (Germany) of HCPs reported their institution did not stock these agents. In both countries, key reasons for delaying treatment were lack of bypassing agent availability, HCP experience/education of bleed disorders and internal process time. Conclusion Barriers to fast treatment of bleeds in patients with haemophilia and inhibitors were identified in non‐HTCs in the United States and Germany. These could be reduced by improving the availability of treatment guidelines, bypassing agents and HCP education/training.
- Open Access
- 13 September 2019
- Published by Wiley in Haemophilia
- Vol. 25 (6) , 969-978
Clinical evaluation of bleeds and response to haemostatic treatment in patients with acquired haemophilia: A global expert consensus statement
Background: Acquired haemophilia (AH) is a rare bleeding disorder with significant morbidity and mortality. Most patients initially present to physicians without experience of the disease, delaying diagnosis and potentially worsening outcomes. Existing guidance in AH is limited to clinical opinion of few experts and does not address monitoring bleeds in specific anatomical locations.Aim: Derive consensus from a large sample of experts around the world in monitoring bleeding patients with AH.Methods: Using the Delphi methodology, a structured survey, designed to derive consensus on how to monitor bleeding patients with AH, was developed by a steering committee for completion by a group of haematologists with an interest in AH. Consensus was defined as ≥75% agreement with a given survey statement. After three rounds of survey refinement, a final list of consensus statements was compiled.Results: Thirty‐six global specialists in AH participated. The participants spanned 20 countries and had treated a median of 12.0 (range, 1‐50) patients with AH within the preceding 5 years. Consensus was achieved in all items after three survey rounds. In addition to statements on general management of bleeding patients, consensus statements in the following areas were presented: urinary tract, gastrointestinal tract, muscles, skin, joints, nose, pharynx, mouth, intracranial and postpartum.Conclusions: Here, we present consensus statements derived from a broad sample of global specialists to address monitoring of location‐specific bleeds and evaluating efficacy of bleeding treatment in patients with AH. These statements could be applied in practice by treating physicians and validated by individual population surveys.
- 13 September 2019
- Published by Wiley in Haemophilia
- Vol. 25 (6) , 969-978
Open AccessClinical evaluation of bleeds and response to haemostatic treatment in patients with acquired haemophilia: A global expert consensus statement
Background: Acquired haemophilia (AH) is a rare bleeding disorder with significant morbidity and mortality. Most patients initially present to physicians without experience of the disease, delaying diagnosis and potentially worsening outcomes. Existing guidance in AH is limited to clinical opinion of few experts and does not address monitoring bleeds in specific anatomical locations.Aim: Derive consensus from a large sample of experts around the world in monitoring bleeding patients with AH.Methods: Using the Delphi methodology, a structured survey, designed to derive consensus on how to monitor bleeding patients with AH, was developed by a steering committee for completion by a group of haematologists with an interest in AH. Consensus was defined as ≥75% agreement with a given survey statement. After three rounds of survey refinement, a final list of consensus statements was compiled.Results: Thirty‐six global specialists in AH participated. The participants spanned 20 countries and had treated a median of 12.0 (range, 1‐50) patients with AH within the preceding 5 years. Consensus was achieved in all items after three survey rounds. In addition to statements on general management of bleeding patients, consensus statements in the following areas were presented: urinary tract, gastrointestinal tract, muscles, skin, joints, nose, pharynx, mouth, intracranial and postpartum.Conclusions: Here, we present consensus statements derived from a broad sample of global specialists to address monitoring of location‐specific bleeds and evaluating efficacy of bleeding treatment in patients with AH. These statements could be applied in practice by treating physicians and validated by individual population surveys.
- 13 July 2018
- Published by Wiley in Haemophilia
- Vol. 24 (4) , E275-E277
Recombinant activated factor VII in approved indications: Update on safety
- 13 July 2018
- Published by Wiley in Haemophilia
- Vol. 24 (4) , E275-E277
Recombinant activated factor VII in approved indications: Update on safety
- 9 May 2018
- Published by Wiley in Haemophilia
- Vol. 24 (4) , 536-547
Methodologies for data collection in congenital haemophilia with inhibitors (CHwI): critical assessment of the literature and lessons learned from recombinant factor VIIa
Aims: To systematically review the effectiveness of on‐demand treatment with recombinant coagulation factor VIIa (rFVIIa) in congenital haemophilia with inhibitors and, if feasible, perform a meta‐analysis of the data.Materials and methods: Publications from Embase®, MEDLINE®, MEDLINE® In‐Process and the Cochrane Central Register of Controlled Trials were searched. Selected publications were reviewed for inclusion by two independent expert reviewers. Discrepancies were reconciled by a third independent reviewer. Data from selected studies were extracted using a predefined grid to ensure uniform and comparable results were captured.Results: A systematic search (cut‐off date of 2 May 2016) identified 20 studies (13 observational; seven randomized controlled trials). All studies were of sufficient quality to include in this analysis and comprised 1221 participants, with 5981 bleeds in 746 individuals treated with rFVIIa. Haemostatic overall effectiveness of the individual studies identified ranged from 68% to 100% at ≤12 hours, 86% to 96% at 13‐24 hours and 76% to 99% at 24‐48 hours with rFVIIa <100 μg/kg, with similar rates reported for the ≥250 μg/kg dose. However, heterogeneity between the studies precluded pooling of results.Conclusions: Data from the individual studies confirmed that rFVIIa is an effective therapy for the on‐demand treatment of bleeds in congenital haemophilia with inhibitors. However, the high levels of heterogeneity between studies precluded pooling of results for a valid, reliable or precise summary measure. There remains a need to implement standardized clinical definitions and measurements for the effectiveness and safety of haemophilia therapies in future clinical trials.
- 9 May 2018
- Published by Wiley in Haemophilia
- Vol. 24 (4) , 536-547
Methodologies for data collection in congenital haemophilia with inhibitors (CHwI): critical assessment of the literature and lessons learned from recombinant factor VIIa
Aims: To systematically review the effectiveness of on‐demand treatment with recombinant coagulation factor VIIa (rFVIIa) in congenital haemophilia with inhibitors and, if feasible, perform a meta‐analysis of the data.Materials and methods: Publications from Embase®, MEDLINE®, MEDLINE® In‐Process and the Cochrane Central Register of Controlled Trials were searched. Selected publications were reviewed for inclusion by two independent expert reviewers. Discrepancies were reconciled by a third independent reviewer. Data from selected studies were extracted using a predefined grid to ensure uniform and comparable results were captured.Results: A systematic search (cut‐off date of 2 May 2016) identified 20 studies (13 observational; seven randomized controlled trials). All studies were of sufficient quality to include in this analysis and comprised 1221 participants, with 5981 bleeds in 746 individuals treated with rFVIIa. Haemostatic overall effectiveness of the individual studies identified ranged from 68% to 100% at ≤12 hours, 86% to 96% at 13‐24 hours and 76% to 99% at 24‐48 hours with rFVIIa <100 μg/kg, with similar rates reported for the ≥250 μg/kg dose. However, heterogeneity between the studies precluded pooling of results.Conclusions: Data from the individual studies confirmed that rFVIIa is an effective therapy for the on‐demand treatment of bleeds in congenital haemophilia with inhibitors. However, the high levels of heterogeneity between studies precluded pooling of results for a valid, reliable or precise summary measure. There remains a need to implement standardized clinical definitions and measurements for the effectiveness and safety of haemophilia therapies in future clinical trials.